Impact of empagliflozin on diabetic kidney disease #MMPMID28035769
Koya D
J Diabetes Investig 2017[Sep]; 8 (5): 658-60 PMID28035769show ga
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule?glomerular feedback, thereby protect against diabetes?induced caidio?renal injuries.